EV Biotech provides an AI‑driven platform, ArtemisAI, that designs and optimizes microbial production strains and the associated fermentation processes. By combining metabolic modeling, machine‑learning predictions, and in‑house lab development, they accelerate strain engineering, improve yields, and support scale‑up to industrial volumes, partnering with specialty ingredient, food, beverage, pharma, and cosmetic companies and sharing commercial upside through royalties or joint ventures.
Funding
$4.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OFFFounders
Product
Problem
Developing microbial production strains that achieve high yields and can be scaled to industrial volumes is time‑consuming, costly, and requires specialized expertise in both metabolic engineering and bioprocess development. Companies often lack integrated tools to rapidly design, test, and optimize microbes while ensuring the process remains robust at scale.
Solution
EV Biotech offers a collaborative platform that combines AI‑driven metabolic modeling with deep fermentation know‑how to design and optimize microbial strains for target molecules. Through its proprietary ArtemisAI system, the company accelerates strain engineering, predicts performance, and refines process parameters using real‑world data. EV Biotech conducts laboratory‑scale development, validates high‑performance microbes, and supports scale‑up to industrial production, sharing commercial upside via royalties, licenses, or joint ventures. This end‑to‑end approach reduces development timelines, improves yields, and de‑risks the transition from lab to market.
Target Audience
Primary customers are specialty ingredient manufacturers, food and beverage producers, and pharmaceutical or cosmetic companies seeking to develop or improve bio‑based products through precision fermentation.
Features
- AI‑powered metabolic pathway modeling integrated with machine‑learning predictions to identify optimal genetic modifications
- Automated design‑build-test cycles in EV Biotech’s own laboratory for rapid strain prototyping
- Process‑level optimization that aligns cellular engineering with industrial fermentation conditions
- Real‑world data integration to continuously refine strain and process performance during scale‑up
- Co‑development partnership model with shared revenue mechanisms (royalties, licensing, joint ventures)
- Capability to engineer regulatory networks at both cellular and bioprocess levels for robust, scalable production